Therefore, we conduct a systematic review and network meta-analysis (NMA) to provide a detailed assessment of the efficacy of PCSK9 inhibitor agents such as alirocumab, evolocumab, and inclisiran and powerful statins including atorvastatin and rosuvastatin for reducing LDL-C in patients with hyperlipidemia. Here, PCSK9 is linked to hyperlipidemia.